Immunic (IMUX) announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares of common stock (or pre-funded warrants) expiring on December 31, 2025, (iii) and Series B warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. All of the securities to be sold in the proposed offering will be offered by Immunic. The company intends to use the net proceeds received from the proposed offering to fund its clinical trials and operations and for other general corporate purposes. Leerink Partners is acting as the sole bookrunner for the offering.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Immunic price target lowered to $5 from $6 at B. Riley
- Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
- Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating
- Positive Phase 2 Trial Results for VidoCa in PMS Bolster Buy Rating for Immunic
- Biotech Alert: Searches spiking for these stocks today